ECSP13012794A - Anticuerpos anti-cd38 - Google Patents

Anticuerpos anti-cd38

Info

Publication number
ECSP13012794A
ECSP13012794A ECSP13012794A ECSP13012794A EC SP13012794 A ECSP13012794 A EC SP13012794A EC SP13012794 A ECSP13012794 A EC SP13012794A EC SP13012794 A ECSP13012794 A EC SP13012794A
Authority
EC
Ecuador
Prior art keywords
antibodies
cynomolgo
bind
therapeutic
human
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Jathleen Ann Elias
Gregory Landes
Shweta Singh
Wouter Korver
Andrew Walling Drake
Frendscho Mary Haak
Gyorgy Pal Snell
Vinay Bhaskar
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP13012794A publication Critical patent/ECSP13012794A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ECSP13012794 2010-12-30 2013-07-29 Anticuerpos anti-cd38 ECSP13012794A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201061428699P 2010-12-30 2010-12-30
US201161470382P 2011-03-31 2011-03-31
US201161470406P 2011-03-31 2011-03-31
US201161485104P 2011-05-11 2011-05-11

Publications (1)

Publication Number Publication Date
ECSP13012794A true ECSP13012794A (es) 2013-10-31

Family

ID=45498158

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012794 ECSP13012794A (es) 2010-12-30 2013-07-29 Anticuerpos anti-cd38

Country Status (38)

Country Link
US (11) US9102744B2 (OSRAM)
EP (6) EP3789404A1 (OSRAM)
JP (10) JP6148984B2 (OSRAM)
KR (5) KR102070326B1 (OSRAM)
CN (4) CN107365385A (OSRAM)
AR (1) AR084747A1 (OSRAM)
AU (3) AU2011351921B2 (OSRAM)
BR (1) BR112013017009B1 (OSRAM)
CA (1) CA2822061C (OSRAM)
CO (1) CO6761368A2 (OSRAM)
CR (1) CR20130313A (OSRAM)
CY (3) CY1122161T1 (OSRAM)
DK (3) DK2658871T3 (OSRAM)
EA (2) EA029303B1 (OSRAM)
EC (1) ECSP13012794A (OSRAM)
ES (3) ES2690095T3 (OSRAM)
GE (1) GEP20166493B (OSRAM)
HR (3) HRP20181245T1 (OSRAM)
HU (3) HUE038535T2 (OSRAM)
IL (1) IL226973A (OSRAM)
JO (2) JOP20210044A1 (OSRAM)
LT (3) LT3284754T (OSRAM)
MA (1) MA34763B1 (OSRAM)
MX (2) MX350903B (OSRAM)
MY (1) MY160499A (OSRAM)
NZ (2) NZ612272A (OSRAM)
PE (1) PE20140247A1 (OSRAM)
PL (3) PL3284754T3 (OSRAM)
PT (3) PT2658871T (OSRAM)
RS (3) RS61280B1 (OSRAM)
SG (1) SG191211A1 (OSRAM)
SI (3) SI2658871T1 (OSRAM)
SM (2) SMT201800388T1 (OSRAM)
TR (1) TR201808709T4 (OSRAM)
TW (1) TWI564304B (OSRAM)
UY (1) UY33850A (OSRAM)
WO (2) WO2012092612A1 (OSRAM)
ZA (1) ZA201304696B (OSRAM)

Families Citing this family (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
HUE035250T2 (hu) 2005-10-12 2018-05-02 Morphosys Ag Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PL2621531T3 (pl) 2010-09-27 2017-07-31 Morphosys Ag Przeciwciało anty-CD38 i lenalidomid lub bortezomib do leczenia szpiczaka mnogiego i NHL
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EA034989B1 (ru) 2011-10-28 2020-04-15 Тева Фармасьютикал Австралия Пти Лтд Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон
WO2014010586A1 (ja) 2012-07-10 2014-01-16 武田薬品工業株式会社 注射用製剤
AU2013322806C1 (en) 2012-09-25 2018-03-08 Morphosys Ag Combinations and uses thereof
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
CA2909952C (en) * 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CA2927099A1 (en) * 2013-10-31 2015-05-07 Sanofi Specific anti-cd38 antibodies for treating human cancers
MY176522A (en) 2013-11-04 2020-08-13 Ichnos Sciences SA Production of t cell retargeting hetero-dimeric immunoglobulins
JP2017506640A (ja) * 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) * 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2016011210A2 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
SG11201701867SA (en) * 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
SG11201703251TA (en) 2014-10-29 2017-05-30 Teva Pharmaceuticals Australia Pty Ltd INTERFERON α2B VARIANTS
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
WO2016089960A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
ES2927119T3 (es) * 2015-04-08 2022-11-02 Sorrento Therapeutics Inc Productos terapéuticos de anticuerpos que se unen a CD38
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
MA42136A (fr) 2015-05-20 2018-03-28 Janssen Biotech Inc Anticorps anti-cd38 pour le traitement de l'amyloïdose à chaînes légères et d'autres tumeurs malignes hématologiques positives à cd38
LT3303373T (lt) 2015-05-30 2020-07-10 Molecular Templates, Inc. Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
US10668149B2 (en) * 2015-06-22 2020-06-02 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP3313441B1 (en) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
MX2017015817A (es) 2015-07-06 2018-04-10 Ucb Biopharma Sprl Anticuerpos de union a tau.
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
US20180264038A1 (en) 2015-09-28 2018-09-20 Regents Of The University Of Minnesota Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity
ES2894304T3 (es) 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
PH12018500950B1 (en) 2015-11-03 2023-09-20 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
PL3380620T3 (pl) 2015-11-23 2024-11-12 Novartis Ag Zoptymalizowane lentiwirusowe wektory transferowe i ich zastosowanie
CA3009709A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
EP3423498A1 (en) * 2016-03-04 2019-01-09 MorphoSys AG Clinical assessment of m-protein response in multiple myeloma
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
TWI788286B (zh) 2016-04-13 2023-01-01 法商賽諾菲公司 三特異性和/或三價結合蛋白
EP4257193A3 (en) 2016-04-13 2024-01-24 Sanofi Trispecific and/or trivalent binding proteins
EP3452109A1 (en) * 2016-05-03 2019-03-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Cd31shed as a molecular target for imaging of inflammation
WO2018002181A1 (en) * 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
JP7316930B2 (ja) * 2016-07-15 2023-07-28 武田薬品工業株式会社 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
WO2018015498A1 (en) 2016-07-20 2018-01-25 Hybrigenics Sa Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
CN110337590A (zh) * 2016-11-04 2019-10-15 奥胡斯大学 以新生儿Fc受体过表达为特征的肿瘤的识别和治疗
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018159549A1 (ja) * 2017-03-01 2018-09-07 株式会社膠原病研究所 自己免疫疾患の予防および／または治療剤、並びに、ワクチン
KR20190133005A (ko) 2017-03-24 2019-11-29 젠야쿠코교가부시키가이샤 항 IgM/B 세포 표면 항원 이중 특이성 항체
WO2018183376A1 (en) * 2017-03-28 2018-10-04 Rigel Pharmaceuticals, Inc. Acvr2a-specific antibody and method of use thereof
CA3058966A1 (en) 2017-04-14 2018-10-18 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
KR20250025514A (ko) * 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
KR20250025513A (ko) * 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
CN111051344B (zh) * 2017-06-08 2023-10-27 黑带医疗有限公司 Cd38调节抗体
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018235024A1 (en) * 2017-06-20 2018-12-27 Sorrento Therapeutics, Inc. Cd38 antibody drug conjugate
EP3538645B1 (en) 2017-06-20 2021-01-20 Institut Curie Immune cells defective for suv39h1
EP3434692A1 (en) * 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
AU2018316521B2 (en) * 2017-08-16 2025-01-30 Black Belt Therapeutics Limited CD38 modulating antibody
AU2018316522B2 (en) 2017-08-16 2025-02-20 Black Belt Therapeutics Limited CD38 antibody
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
CA3075399A1 (en) 2017-09-13 2019-03-21 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
US11186649B2 (en) * 2017-10-10 2021-11-30 Sanofi Anti-CD38 antibodies and methods of use
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
CN111566124A (zh) 2017-10-25 2020-08-21 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
SG11202003688PA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Process for generating therapeutic compositions of engineered cells
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
EP3704229B1 (en) 2017-11-01 2023-12-20 Juno Therapeutics, Inc. Process for producing a t cell composition
CN111542545A (zh) 2017-11-03 2020-08-14 索伦托治疗有限公司 Cd38定向嵌合抗原受体构建体
EP3717517A1 (en) * 2017-11-30 2020-10-07 H. Hoffnabb-La Roche Ag Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1
CN111587254B (zh) * 2017-12-05 2025-02-25 特拉维夫医疗中心医学研究基础设施及卫生服务基金 包含抗cd38和抗cd138嵌合抗原受体的t-细胞及其用途
KR102853341B1 (ko) 2017-12-08 2025-09-02 주노 쎄러퓨티크스 인코퍼레이티드 조작된 ｔ 세포의 조성물을 제조하는 방법
CA3084446A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
SG11202005228YA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Serum-free media formulation for culturing cells and methods of use thereof
CA3088199A1 (en) * 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
CA3095086A1 (en) * 2018-03-28 2019-10-03 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
CN108318689A (zh) * 2018-04-09 2018-07-24 北京大学深圳研究生院 一种多发性骨髓瘤的诊断方法
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
CN108752475B (zh) * 2018-06-14 2021-07-30 北京智仁美博生物科技有限公司 抗人cd38抗体及其用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP7534281B2 (ja) 2018-07-13 2024-08-14 ジェンマブ エー／エス Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療
MY205398A (en) 2018-07-13 2024-10-19 Genmab As Variants of cd38 antibody and uses thereof
KR20210059715A (ko) 2018-08-09 2021-05-25 주노 쎄러퓨티크스 인코퍼레이티드 통합된 핵산 평가 방법
CA3111651A1 (en) * 2018-09-11 2020-03-19 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd38 antibody, antigen-binding fragment thereof, and pharmaceutical use
CN109053892B (zh) * 2018-09-19 2021-03-26 苏州思坦维生物技术股份有限公司 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用
JP7462621B2 (ja) 2018-10-09 2024-04-05 サノフイ 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法
US20210388106A1 (en) 2018-10-26 2021-12-16 Teneobio, Inc. Heavy chain antibodies binding to cd38
CA3117419A1 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
PE20211058A1 (es) 2018-11-01 2021-06-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
AU2019395841B2 (en) 2018-12-14 2025-02-27 Morphosys Ag Antibody formulations
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
CA3127660A1 (en) 2019-01-23 2020-07-30 Millennium Pharmaceuticals, Inc. Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors
EP3914358A1 (en) 2019-01-23 2021-12-01 Millennium Pharmaceuticals, Inc. Anti-cd38 antibodies
WO2020152290A1 (en) * 2019-01-23 2020-07-30 Encefa Cd31 competitors and uses thereof
US12479817B2 (en) 2019-02-15 2025-11-25 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020222345B2 (en) 2019-02-15 2022-11-17 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
SG11202107319PA (en) 2019-03-15 2021-08-30 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US20200316197A1 (en) * 2019-03-28 2020-10-08 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
US20200308296A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
WO2020194243A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone
US20200330593A1 (en) * 2019-03-28 2020-10-22 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone
US20220144966A1 (en) * 2019-03-29 2022-05-12 Sorrento Therapeutics, Inc. Engineered Variant Antibodies that Bind CD38
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
CN113950484B (zh) * 2019-04-09 2025-07-29 赛诺菲 三特异性结合蛋白、其方法和用途
CN114025788A (zh) 2019-05-01 2022-02-08 朱诺治疗学股份有限公司 从经修饰的tgfbr2基因座表达重组受体的细胞、相关多核苷酸和方法
MX2021013223A (es) 2019-05-01 2022-02-17 Juno Therapeutics Inc Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
JP7705353B2 (ja) 2019-06-10 2025-07-09 武田薬品工業株式会社 Ｃｄ３８抗体を使用する併用療法
PH12021553254A1 (en) 2019-06-27 2022-09-19 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
CA3142632A1 (en) * 2019-07-03 2021-01-07 Crystal Bioscience Inc. Anti-cd38 antibody and methods of use thereof
AU2020318781A1 (en) 2019-07-23 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Immune cells defective for SUV39H1
CN112538114B (zh) * 2019-09-20 2025-05-02 上海普铭生物科技有限公司 抗人cd38抗体及其应用
WO2021092332A1 (en) * 2019-11-07 2021-05-14 Ohio State Innovation Foundation Methods and compositions relating to selective intracellular delivery of cd38 inhibitors
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
IL293751A (en) 2019-12-18 2022-08-01 Teneofour Inc Heavy chain antibodies binding to cd38
JP2023506958A (ja) 2019-12-20 2023-02-20 ノバルティス アーゲー 骨髄線維症および骨髄異形成症候群を処置するための、デシタビンまたは抗ｐｄ－１抗体スパルタリズマブを伴うかまたは伴わない抗ｔｉｍ－３抗体ｍｂｇ４５３および抗ｔｇｆ－ベータ抗体ｎｉｓ７９３の組合せ
KR20220130724A (ko) 2020-01-16 2022-09-27 젠맵 에이/에스 Cd38 항체의 제제 및 그의 용도
CN115427458A (zh) 2020-02-28 2022-12-02 塔拉克治疗公司 转谷氨酰胺酶介导的缀合
IL296723A (en) 2020-03-26 2022-11-01 Seagen Inc Methods of treating multiple myeloma
WO2021207689A2 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
EP4121112A4 (en) 2020-05-08 2023-11-15 The University Of Southern California Site-specific antibody-drug conjugates by adp-ribosyl cyclases
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20240216508A1 (en) 2020-06-26 2024-07-04 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
WO2021260657A1 (en) 2020-06-26 2021-12-30 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
CA3190266A1 (en) 2020-07-30 2022-02-03 Institut Curie Immune cells defective for socs1
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4240756A1 (en) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
US20220202859A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
CN116997654A (zh) 2021-03-17 2023-11-03 第一三共株式会社 编码抗乙酰胆碱受体自身抗体的嵌合受体的基因
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
US20240384293A1 (en) 2021-04-27 2024-11-21 Novartis Ag Viral vector production system
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
US20240269282A1 (en) 2021-05-10 2024-08-15 Institut Curie Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases
US20220387488A1 (en) 2021-05-12 2022-12-08 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
AR125852A1 (es) 2021-05-12 2023-08-16 Crispr Therapeutics Ag Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en tratamiento de tumores sólidos
US20240261446A1 (en) * 2021-05-17 2024-08-08 Université de Liège Anti-cd38 single domain antibodies in disease monitoring and treatment
EP4346912A1 (en) 2021-05-25 2024-04-10 Institut Curie Myeloid cells overexpressing bcl2
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
JP2024527047A (ja) 2021-07-28 2024-07-19 ジェネンテック， インコーポレイテッド 血液がんの処置のためのｉｌ１５／ｉｌ１５ｒアルファヘテロ二量体ｆｃ融合タンパク質
WO2023017392A1 (en) 2021-08-13 2023-02-16 3M Innovative Properties Company Antistatic fabric article
CN113896802A (zh) * 2021-10-09 2022-01-07 宜明昂科生物医药技术（上海）有限公司 靶向cd47和cd38的重组融合蛋白及其制备和用途
EP4456910A1 (en) 2021-12-28 2024-11-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
JP2025504002A (ja) 2022-01-28 2025-02-06 ジュノー セラピューティクス インコーポレイテッド 細胞組成物を製造する方法
JP2025508739A (ja) 2022-02-18 2025-04-10 ラクテン・メディカル，インコーポレイテッド 抗プログラム細胞死リガンド１（ｐｄ－ｌ１）抗体分子、それをコードするポリヌクレオチド、および使用方法
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
JP2025531850A (ja) 2022-09-08 2025-09-25 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ
AU2023338115A1 (en) * 2022-09-09 2025-02-27 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies for treating patients with moderate to severe systemic lupus erythematosus
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
EP4612177A1 (en) 2022-10-31 2025-09-10 Genmab A/S Cd38 antibodies and uses thereof
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
KR20250121074A (ko) 2022-12-09 2025-08-11 주노 쎄러퓨티크스 인코퍼레이티드 홀로그래픽 이미징을 사용하여 세포 표현형을 예측하기 위한 기계 학습 방법
KR20250135226A (ko) 2023-01-06 2025-09-12 다케다 야쿠힌 고교 가부시키가이샤 자가면역 질환의 치료를 위한 항-cd38 항체
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2025042742A1 (en) 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025153973A1 (en) 2024-01-16 2025-07-24 MorphoSys GmbH Highly concentrated liquid formulations for antibodies
WO2025193746A1 (en) 2024-03-12 2025-09-18 Takeda Pharmaceutical Company Limited Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia
WO2025235919A1 (en) 2024-05-09 2025-11-13 Takeda Pharmaceutical Company Limited Dosing regimens of anti-cd38 antibodies for treatment of subjects with immunoglobulin a nephropathy
CN119119277B (zh) * 2024-10-24 2025-09-09 深圳技术大学 一种靶向cd38的纳米抗体、药物组合物及其应用

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
EP0271581B1 (en) 1986-04-17 1993-01-13 Kyowa Hakko Kogyo Co., Ltd. Novel compounds dc-88a and dc-89a1 and process for their preparation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5084468A (en) 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE911537A1 (en) 1990-05-07 1991-11-20 Scripps Clinic Res Intermediates in the formation of the calicheamicin and¹esperamicin oligosaccharides
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU6123894A (en) * 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ES2233928T3 (es) 1993-10-01 2005-06-16 Teikoku Hormone Mfg. Co., Ltd. Derivados de dolastatina.
CA2165819C (en) 1994-04-22 2005-12-27 Nobuyoshi Amishiro Dc-89 derivatives
JPH07309761A (ja) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
DE69626849T2 (de) 1995-12-22 2003-12-24 Bristol-Myers Squibb Co., Princeton Verzweigte hydrazongruppen enthaltende kuppler
ES2273415T3 (es) * 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US7112661B1 (en) 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
MXPA03002974A (es) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
EP1333032A4 (en) 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk PROCESS FOR PURIFYING ANTIBODY
IT1320715B1 (it) 2000-10-19 2003-12-10 Cselt Centro Studi Lab Telecom Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
EP2009027B1 (en) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
KR20030033007A (ko) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
US7497862B2 (en) 2001-08-03 2009-03-03 Tyco Healthcare Group Lp Tissue marking apparatus and method
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
JP4741838B2 (ja) 2002-07-31 2011-08-10 シアトル ジェネティクス，インコーポレーテッド 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
DE10246870B3 (de) 2002-10-08 2004-04-29 Renk Aktiengesellschaft Elektro-Hydrodynamische Überlagerungslenkung
CN100526460C (zh) * 2002-11-08 2009-08-12 麒麟医药株式会社 朊病毒蛋白活性降低的转基因有蹄类动物及其用途
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
EP3524611B1 (en) 2003-05-20 2020-12-30 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CN104998273A (zh) 2003-11-06 2015-10-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
WO2006125640A2 (en) * 2005-05-24 2006-11-30 Morphosys Ag Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
ES2533695T3 (es) 2004-03-02 2015-04-14 Seattle Genetics, Inc. Anticuerpos cargados parcialmente y métodos para su conjugación
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EA037929B1 (ru) 2005-03-23 2021-06-08 Генмаб А/С Антитела к cd38 человека и их применение
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
CA2605507C (en) 2005-04-19 2016-06-28 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
PL1912671T3 (pl) 2005-07-18 2018-02-28 Seattle Genetics, Inc. Koniugaty beta-glukuronid-linker-lek
CA2617907A1 (en) 2005-08-05 2007-02-15 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
HUE035250T2 (hu) 2005-10-12 2018-05-02 Morphosys Ag Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása
US7847105B2 (en) 2005-10-26 2010-12-07 Medarex, Inc. Methods and compounds for preparing CC-1065 analogs
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
KR20080114709A (ko) 2006-02-02 2008-12-31 신타가 비.브이. 수용성 ｃｃ-1065 유사체 및 그들의 결합체
WO2008007648A1 (fr) 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
ME03503B (me) 2006-09-26 2020-04-20 Genmab As Anti-cd38 plus kortkosteroidni plus ne-kortikosteroidni hemoterapeutik za tretiranje tumora
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US8680293B2 (en) 2007-08-01 2014-03-25 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
JP5737944B2 (ja) * 2007-12-17 2015-06-17 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 間質性膀胱炎の治療
EP2300052A4 (en) 2008-06-16 2012-11-14 Immunogen Inc NEW SYNERGISTIC EFFECTS
JP2012506695A (ja) * 2008-08-20 2012-03-22 ヤンセン バイオテツク，インコーポレーテツド 改変された抗ｉｌ−１３抗体、組成物、方法、及び使用
JP5677970B2 (ja) 2008-11-03 2015-02-25 シンタルガ・ビーブイ 新規ｃｃ−１０６５類似体およびその複合体
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
JP5725508B2 (ja) 2009-03-25 2015-05-27 国立大学法人東北大学 Ｌｈ型二重特異性抗体
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
SI2580243T1 (sl) 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
PL2621531T3 (pl) 2010-09-27 2017-07-31 Morphosys Ag Przeciwciało anty-CD38 i lenalidomid lub bortezomib do leczenia szpiczaka mnogiego i NHL
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
GB2486424A (en) 2010-12-13 2012-06-20 Univ Sussex Markers for plasma cell disorders
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012118750A2 (en) 2011-02-28 2012-09-07 Genentech, Inc. Biological markers and methods for predicting response to b-cell antagonists
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
GB201203938D0 (en) 2012-03-06 2012-04-18 Binding Site Group The Ltd Assay system
GB201212900D0 (en) 2012-07-20 2012-09-05 Binding Site Group The Ltd Triage scoring system
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US20160075766A1 (en) 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
BR112016002001B1 (pt) 2013-07-30 2023-04-25 SBI Biotech Co., Ltd Uso de anticorpo monoclonal, método in vitro para detectar células b ativadas, reagente para detectar células b ativadas, método in vitro para suprimir a atividade b das células ativadas, e anticorpo monoclonal
CA2927099A1 (en) 2013-10-31 2015-05-07 Sanofi Specific anti-cd38 antibodies for treating human cancers
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
SG11201701867SA (en) 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
MA41555A (fr) 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
MX380557B (es) 2015-05-13 2025-03-12 Morphosys Ag Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm).
MA42136A (fr) 2015-05-20 2018-03-28 Janssen Biotech Inc Anticorps anti-cd38 pour le traitement de l'amyloïdose à chaînes légères et d'autres tumeurs malignes hématologiques positives à cd38
PH12018500950B1 (en) 2015-11-03 2023-09-20 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
US20170121417A1 (en) 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
JP7316930B2 (ja) * 2016-07-15 2023-07-28 武田薬品工業株式会社 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料
US20180117150A1 (en) 2016-11-01 2018-05-03 Janssen Biotech, Inc. Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CA3088199A1 (en) * 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
US20210269546A1 (en) * 2018-07-11 2021-09-02 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38

Also Published As

Publication number Publication date
JP6563446B2 (ja) 2019-08-21
JP2019205454A (ja) 2019-12-05
LT3284754T (lt) 2021-01-25
US10494444B2 (en) 2019-12-03
ES2841299T3 (es) 2021-07-08
JP7096301B2 (ja) 2022-07-05
IL226973A (en) 2016-08-31
PT2658870T (pt) 2018-07-03
EP3284755B1 (en) 2020-10-07
US20140155584A1 (en) 2014-06-05
LT2658871T (lt) 2018-09-10
KR102070326B1 (ko) 2020-01-29
SI3284754T1 (sl) 2021-03-31
WO2012092616A1 (en) 2012-07-05
SMT201800405T1 (it) 2018-09-13
HK1245284A1 (en) 2018-08-24
JP2018019689A (ja) 2018-02-08
US20180066069A1 (en) 2018-03-08
AU2011351921A1 (en) 2013-07-11
US9102744B2 (en) 2015-08-11
US20230037373A1 (en) 2023-02-09
JP6621447B2 (ja) 2019-12-18
KR101945002B1 (ko) 2019-02-07
AU2019264573A1 (en) 2019-12-05
DK2658870T3 (en) 2018-08-06
AU2017204571B2 (en) 2019-09-19
JP6425644B2 (ja) 2018-11-21
JP5843884B2 (ja) 2016-01-13
US9790285B2 (en) 2017-10-17
EP3284754B1 (en) 2020-11-04
CN107365385A (zh) 2017-11-21
CY1123739T1 (el) 2022-03-24
EA201791186A1 (ru) 2017-10-31
CA2822061A1 (en) 2012-07-05
MY160499A (en) 2017-03-15
JP2020022464A (ja) 2020-02-13
US8362211B2 (en) 2013-01-29
EP3789404A1 (en) 2021-03-10
LT2658870T (lt) 2018-09-10
PT2658871T (pt) 2018-08-07
HK1250735A1 (en) 2019-01-11
CA2822061C (en) 2022-10-18
DK2658871T3 (en) 2018-08-13
US20120201827A1 (en) 2012-08-09
KR20140032963A (ko) 2014-03-17
ES2674175T3 (es) 2018-06-27
EP2658870B1 (en) 2018-04-25
US20200031951A1 (en) 2020-01-30
EP3284754A1 (en) 2018-02-21
US20150291702A1 (en) 2015-10-15
HUE038535T2 (hu) 2018-10-29
UY33850A (es) 2012-07-31
PL2658870T3 (pl) 2018-11-30
KR20220139441A (ko) 2022-10-14
EA201390993A1 (ru) 2013-12-30
EP3798231A1 (en) 2021-03-31
KR20190015764A (ko) 2019-02-14
CO6761368A2 (es) 2013-09-30
HRP20181176T1 (hr) 2018-09-21
JP2021019588A (ja) 2021-02-18
US12209138B2 (en) 2025-01-28
ZA201304696B (en) 2014-09-25
JP2021087437A (ja) 2021-06-10
PL2658871T3 (pl) 2018-11-30
CN103282383B (zh) 2017-08-29
BR112013017009A2 (pt) 2017-07-25
SI2658870T1 (sl) 2018-10-30
EP2658870A1 (en) 2013-11-06
US11434304B2 (en) 2022-09-06
MX2013007455A (es) 2013-07-22
EP3284755A1 (en) 2018-02-21
RS57526B1 (sr) 2018-10-31
JP6766233B2 (ja) 2020-10-07
CR20130313A (es) 2013-08-09
CY1122161T1 (el) 2020-07-31
HUE052906T2 (hu) 2021-05-28
DK3284754T3 (da) 2020-12-21
US10336833B2 (en) 2019-07-02
AU2019264573B2 (en) 2021-08-12
JP6840813B2 (ja) 2021-03-10
AU2011351921B2 (en) 2017-04-13
KR102602640B1 (ko) 2023-11-16
PE20140247A1 (es) 2014-03-12
US20250171561A1 (en) 2025-05-29
HUE038727T2 (hu) 2018-11-28
KR102294213B1 (ko) 2021-08-27
CN103282383A (zh) 2013-09-04
CN119775422A (zh) 2025-04-08
SG191211A1 (en) 2013-07-31
EP2658871A1 (en) 2013-11-06
CN113480649B (zh) 2025-01-28
US20130171154A1 (en) 2013-07-04
EP2658871B1 (en) 2018-05-02
PT3284754T (pt) 2020-12-21
JP6148984B2 (ja) 2017-06-14
EA029303B1 (ru) 2018-03-30
MA34763B1 (fr) 2013-12-03
KR102451597B1 (ko) 2022-10-06
US9676869B2 (en) 2017-06-13
BR112013017009B1 (pt) 2022-07-26
NZ705848A (en) 2016-07-29
JP2014509837A (ja) 2014-04-24
JP2016121139A (ja) 2016-07-07
CY1122165T1 (el) 2020-07-31
MX350903B (es) 2017-09-25
JP2016034954A (ja) 2016-03-17
GEP20166493B (en) 2016-06-27
PL3284754T3 (pl) 2021-04-06
HRP20181245T1 (hr) 2018-10-05
HRP20201996T1 (hr) 2021-02-05
JOP20210044A1 (ar) 2017-06-16
US20180016349A1 (en) 2018-01-18
WO2012092612A1 (en) 2012-07-05
JP2014509187A (ja) 2014-04-17
ES2690095T3 (es) 2018-11-19
TWI564304B (zh) 2017-01-01
NZ612272A (en) 2015-04-24
AR084747A1 (es) 2013-06-05
SMT201800388T1 (it) 2018-09-13
US20150203587A1 (en) 2015-07-23
JP7315598B2 (ja) 2023-07-26
MX2020012426A (es) 2021-02-18
AU2017204571A1 (en) 2017-07-27
CN113480649A (zh) 2021-10-08
RS61280B1 (sr) 2021-02-26
TW201247705A (en) 2012-12-01
KR20200009142A (ko) 2020-01-29
RS57494B1 (sr) 2018-10-31
JP6425635B2 (ja) 2018-11-21
SI2658871T1 (sl) 2018-11-30
US8926969B2 (en) 2015-01-06
TR201808709T4 (tr) 2018-07-23
KR20210107892A (ko) 2021-09-01
JP2018029581A (ja) 2018-03-01
US20200040105A1 (en) 2020-02-06
JOP20110402B1 (ar) 2021-08-17

Similar Documents

Publication Publication Date Title
ECSP13012794A (es) Anticuerpos anti-cd38
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
ECSP14004976A (es) Anticuerpos anti-il-36r
EA201401204A1 (ru) Антитела к il-23p19
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
AR076196A1 (es) Anticuerpos biespecificos anti-erbb-3/anti-c-met
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
MX340295B (es) Anticuerpos monoclonales anti-c-met.
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
ECSP14012726A (es) Compuestos terapéuticamente activos y sus métodos de uso
UA117072C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
BR112012011317A2 (pt) antagonistas espiro-oxindóis de mdm2
PL3791896T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
UY33274A (es) Proteínas de unión a basigina
CO6721048A2 (es) Anticuerpos que se unen a notum pectinacetilesterasa
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
GT201500124A (es) Forma sòlida de un derivado de dihidro-pirido-oxazina
UY34081A (es) Composición farmacéutica que comprende drotaverina
TN2013000265A1 (en) Anti-cd38 antibodies